- Home
- BIIB vs ADM Comparison
BIIB vs ADM Comparison
Compare BIIB & ADM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BIIB | ADM |
|---|---|---|
| Founded | 1978 | 1902 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Packaged Foods |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.2B | 30.4B |
| IPO Year | 1991 | N/A |
Fundamental Metrics
Financial Performance| Metric | BIIB | ADM |
|---|---|---|
| Price | $173.17 | $58.42 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 22 | 6 |
| Target Price | ★ $177.40 | $55.67 |
| AVG Volume (30 Days) | 2.7M | ★ 2.9M |
| Earning Date | 10-30-2025 | 02-03-2026 |
| Dividend Yield | N/A | ★ 3.50% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 10.97 | 2.46 |
| Revenue | $10,065,900,000.00 | ★ $83,211,000,000.00 |
| Revenue This Year | $3.61 | N/A |
| Revenue Next Year | N/A | $2.85 |
| P/E Ratio | ★ $15.93 | $23.66 |
| Revenue Growth | ★ 4.77 | N/A |
| 52 Week Low | $110.04 | $40.98 |
| 52 Week High | $185.17 | $65.00 |
Technical Indicators
Market Signals| Indicator | BIIB | ADM |
|---|---|---|
| Relative Strength Index (RSI) | 53.21 | 45.46 |
| Support Level | $168.56 | $57.89 |
| Resistance Level | $175.94 | $60.59 |
| Average True Range (ATR) | 5.21 | 1.31 |
| MACD | -1.78 | -0.07 |
| Stochastic Oscillator | 34.76 | 30.75 |
Price Performance
Historical ComparisonAbout BIIB Biogen Inc.
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
About ADM Archer-Daniels-Midland Company
Archer-Daniels-Midland is a major processor of oilseeds, corn, wheat, and other agricultural commodities. The company is also one of the largest grain merchandisers through its extensive network of logistical assets to store and transport crops around the globe. ADM also runs a nutrition business that focuses on both human and animal ingredients and is a large producer of corn-based sweeteners, starches, and ethanol.